Kuroda Y, Takashima H, Ikeda A, Endo C, Neshige R, Kakigi R, Shibasaki H
Department of Internal Medicine, Saga Medical School, Japan.
J Neurol. 1991 Sep;238(6):309-14. doi: 10.1007/BF00315327.
Fourteen patients with HTLV-1-associated myelopathy were treated with high-dose intravenous gammaglobulin (IVGG). Ten received 10 g/day of IVGG and 4 received 400 mg/kg of body-weight/day of IVGG for 5 consecutive days. Improvement of spastic paraparesis was observed in 10 within 7 days of the commencement of IVGG. The therapeutic effects were sustained for more than 3 weeks in some patients. There were no side effects. Analysis of factors of relevance to the clinical improvement with IVGG showed that the beneficial response was preferentially found in patients having a high CSF titre of anti-HTLV-I antibodies, a high CSF IgG level and a marked brain MRI abnormality.
14例成人T细胞白血病病毒1型相关脊髓病患者接受了大剂量静脉注射丙种球蛋白（IVGG）治疗。10例患者接受每日10 g的IVGG治疗，4例患者接受每日400 mg/kg体重的IVGG治疗，连续治疗5天。在开始IVGG治疗的7天内，10例患者的痉挛性截瘫症状有所改善。部分患者的治疗效果持续超过3周。未出现副作用。对与IVGG临床改善相关因素的分析表明，在脑脊液中抗HTLV-I抗体滴度高、脑脊液IgG水平高且脑部MRI有明显异常的患者中，更易出现有益反应。
